Oruka Therapeutics director proposes $1.93M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. (ORKA) director Kristine Ball reported a proposed sale of 18,000 common shares, with an approximate sale date of November 12, 2026 and an aggregate market value of $1,929,060.
The notice says Ball acquired the shares on November 12, 2026 through a cash exercise of stock options. It lists August 12, 2026 in the field for the plan adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date does the ORKA notice list?
AI-generated analysis. How Rhea-AI works. Not financial advice.